ClinicalTrials.gg
RecruitingNCT07386028Updated Feb 5, 2026

Full Sternotomy vs Mini-sternotomy for Ascending Aortic Pathology

An interventional study of Full sternotomy and J-shaped mini-sternotomy in Ascending Aortic Aneurysm, sponsored by Tomsk Cardiology Research Institute. Recruiting at 1 site in Russia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Tomsk Cardiology Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Jul 2022, registered Dec 2025).
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study investigates outcomes after hemiarch repair in patients with chronic ascending aortic disease. The patients will be divided into two groups according to surgical approach: 100 patients will undergo hemiarch repair via full sternotomy (FS group) and 100 patients will receive hemiarch repair via J-shaped mini-sternotomy (MS group). Early and late outcomes will be recorded.

Read the detailed description
  1. Relevance of the study Hemiarch repair is an effective treatment for patients with ascending aortic aneurysm (AAR). All aortic procedures are routinely performed from full mean sternotomy but nowadays this standard could be performed via minimally invasive approach as well. There are some data that mini-J sternotomy is associated with less blood loss and blood products transfusion, improved lung function and eliminates wound complications risks. The aim of this study was to assess the morbidity and mortality after hemiarch repair via full or J-shaped mini-sternotomy.
  2. Patients and methods Patients who will undergo hemiarch repair procedure via full sternotomy (FS group) will be compared with patients who will receive hemiarch repair via J-shaped mini-sternotomy (MS group). Baseline characteristics including preoperative clinical status, details on surgery, and postoperative outcomes will be compared between these groups. Follow-up data will be recorded.

Imaging All aortic measurements will be assessed by electrocardiography-gated computed tomographic angiography. Postoperative computed tomography of the aorta will be performed within 2 weeks after surgery. Analysis will be performed using 64-slice scanner Discovery NM-CT 570c (GE Healthcare, Milwaukee, WI, USA) with spatial resolution of the angiographic phase ranging from 0.6 to 1.25 mm. All measurements will be taken always in the plane perpendicular to the manually corrected local aortic centre line. Ascending aortic diameter will be measured at the level of the pulmonary artery bifurcation. The maximum aortic diameter (mm) will be measured from the outer contours of the aortic wall. All images will be independently assessed by two experienced cardiologists.

Surgical technique The hemiarch repair is performed via a full sternotomy or J-shaped mini-sternotomy under mild-to-moderate hypothermia (28-30°C) and antegrade cerebral perfusion through the innominate artery with side graft. The distal aortic anastomosis is performed using an open anastomosis fashion and involved resection of the inferior portion of the aortic arch from the base of the innominate artery to the projection of the origin of the left subclavian artery. Near infrared spectroscopy (Invos 5100, Somanetics Corp., USA) is used for cerebral monitoring during the operation. When the target temperature is achieved, lower body circulatory arrest with antegrade cerebral perfusion is initiated. The distal aortic anastomosis is performed with a running 4/0 polypropylene suture with a Dacron graft. Proximal aortic reconstruction including Bentall procedure, David procedure, proximal aortic anastomosis, etc. are performed during the rewarming period. The patient is weaned from cardiopulmonary bypass when the body temperature reached 36°C. The sequence of the surgical steps during the operation are the same for all patients.

Follow-up Follow-up will be performed according to the institutional database supplemented by individual patient records. Data will be obtained via medical records of clinical encounters or phone calls with patients and/or relatives. Postoperative computed tomographic scans will be performed upon discharge, at 12 months from the last procedure and at 60 months thereafter.

02

Conditions studied

  • Ascending Aortic Aneurysm

Keywords

  • ascending aortic aneurysm
  • aortic replacement
  • sternotomy
  • mini-sternotomy
03

In context

Aneurysm, Ascending Aorta

22 studies on the registry are indexed under Aneurysm, Ascending Aorta; 11 are open to participants now.

This study's planned enrollment of 200 is above the median of 164 across 12 interventional studies indexed under Aneurysm, Ascending Aorta.

Browse Aneurysm, Ascending Aorta studies →

Lead sponsor

Tomsk Cardiology Research Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Ascending aorta greater than 5 cm without involving the aortic arch

Exclusion criteria

Exclusion Criteria:

  • Acute aortic dissection or urgent/emergent cases.
  • Redo aortic surgery.
  • Aortic arch surgery.
  • Concomitant CABG or left ventricle restoration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Full Sternotomy

    100 patients who will undergo hemiarch repair via full sternotomy

    Procedure: Full sternotomy

  • Active comparator
    Mini J-Sternotomy

    100 patients who will undergo hemiarch repair via J-shaped mini-sternotomy

    Procedure: J-shaped mini-sternotomy

Interventions

  • ProcedureFull sternotomy

    hemiarch repair via full sternotomy

  • ProcedureJ-shaped mini-sternotomy

    hemiarch repair via J-shaped mini-sternotomy

06

What researchers measure

Primary outcomes

  1. Early mortality

    The difference in the incidence of early mortality between groups (p-value).

    Time frame: during follow-up time - 60 months

Secondary outcomes

  1. Delirium (percent)

    The difference in the incidence of delirium during follow-up (p-value).

    Time frame: Perioperative/Periprocedural

  2. Transient ischemic attack (percent)

    The difference in the incidence of transient ischemic attack during follow-up (p-value).

    Time frame: Perioperative/Periprocedural

  3. Stroke (percent)

    The difference in the incidence of stroke during follow-up (p-value).

    Time frame: during follow-up time - 60 months

  4. Respiratory failure (percent)

    The difference in the incidence of respiratory failure during follow-up (p-value).

    Time frame: Perioperative/Periprocedural

  5. New arrythmia (percent)

    The difference in the incidence of new arrythmia during follow-up (p-value).

    Time frame: during follow-up time - 60 months

  6. Pericardial effusion (percent)

    The difference in the incidence of new arrythmia during follow-up (p-value).

    Time frame: Perioperative/Periprocedural

  7. Heart failure (percent)

    The difference in the incidence of heart failure during follow-up (p-value).

    Time frame: during follow-up time - 60 months

  8. Myocardial infarction (percent)

    The difference in the incidence of myocardial infarction during follow-up (p-value).

    Time frame: during follow-up time - 60 months

  9. Systemic embolism (percent)

    The difference in the incidence of systemic embolism during follow-up (p-value).

    Time frame: during follow-up time - 60 months

  10. Acute kidney injury requiring renal replacement therapy (percent)

    The difference in the incidence of renal replacement therapy during follow-up (p-value).

    Time frame: during follow-up time - 60 months

  11. Re-exploration rate (percent)

    The difference in the incidence of re-operation for bleeding during follow-up (p-value).

    Time frame: during follow-up time - 60 months

07

Study locations

1 of 1 sites recruiting
  • Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
    Tomsk, 634012, Russia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Feb 4, 2026
StartActual
Jul 10, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07386028
Lead sponsor
Tomsk Cardiology Research Institute
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Jul 10, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 5, 2026

Study contacts

Dmitri S. Panfilov, MD, PhD
Contact
pand2006@yandex.ru
+79039130879
Andrey V. Sofronov
Contact
andreysofronov@mail.ru
+79521542201
Boris N. Kozlov, MD, PhD
principal investigator · Cardiology Research Institute, Tomsk National Research Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion